The acquisition comes 14 years after Biogazelle was founded. Since its launch, the company's team has built up vast experience in gene expression analysis. Even more, in 2020, Biogazelle used its technology and equipment to set up a platform – commissioned by the government – to detect the genetic material of the coronavirus in a swab from the nose and throat. Driven by this technological solution for backing COVID testing during the pandemic, the company posted a net profit of over EUR 3 million in 2020.
You are here
CellCarta (Canada) acquires biotech firm Biogazelle (Flanders)
By acquiring Biogazelle, CellCarta further fortifies its leadership position in genomic services with a unique combination of assay development and global clinical trial sample analysis capabilities covering a range of established and cutting-edge genomic technologies. What’s more, the acquisition Biogazelle strengthens the Canadian company’s growth strategy and will allow it to extend genomic services from discovery to clinical settings.
Biogazelle’s exceptional genomics expertise will enable us to further support our clients’ therapeutic development strategies, offering them key solutions to address their clinical challenges and move their immunology and other programs forward.
We are excited to join forces with CellCarta. With both organizations driven by scientific excellence and innovation, it’s the logical next step for us to leverage our know-how and services on a global scale.
To say that Flanders has a diverse and innovation-driven business and research ecosystem for life sciences & health would be an understatement.
Want to unravel this ecosystem in a virtual yet interactive way? Head to the Flanders360 platform and discover 300+ successful companies, universities, R&D centers, incubators and other players active in Flanders’ life sciences & health industry.
Alternatively, check out our industry overview to learn more about the available tax, legal and other incentives for establishing your life sciences & health hub in Flanders.